Trade Royalty Pharma plc - RPRX CFD

Add to favourite

31.19

0.94%

0.13

Low: 30.97

High: 31.41

Market Trading Hours* (UTC) Open now
Closes on Tuesday at 20:00

Mon - Fri: 13:30 - 20:00

Summary
Historical Data

Trading сonditions

Spread

0.13

Long position overnight fee

-0.023485%

Short position overnight fee

0.001262%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	30.92
Open	31.13
1-Year Change	2.67%
Day's Range	30.97 - 31.41

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Mar 31, 2025	30.92	0.07	0.23%	30.85	31.24	30.49
Mar 28, 2025	31.32	-0.23	-0.73%	31.55	31.61	30.92
Mar 27, 2025	31.59	-0.09	-0.28%	31.68	32.18	31.15
Mar 26, 2025	31.48	-1.94	-5.80%	33.42	33.91	31.28
Mar 25, 2025	33.68	0.13	0.39%	33.55	34.08	33.43
Mar 24, 2025	33.66	0.17	0.51%	33.49	33.91	33.46
Mar 21, 2025	33.63	0.51	1.54%	33.12	33.73	32.60
Mar 20, 2025	33.44	0.05	0.15%	33.39	33.45	33.09
Mar 19, 2025	33.36	0.10	0.30%	33.26	33.42	32.99
Mar 18, 2025	33.36	0.39	1.18%	32.97	33.53	32.90
Mar 17, 2025	32.95	0.34	1.04%	32.61	33.20	32.61
Mar 14, 2025	32.71	0.47	1.46%	32.24	32.89	32.24
Mar 13, 2025	32.60	-0.02	-0.06%	32.62	33.07	32.46
Mar 12, 2025	32.79	0.74	2.31%	32.05	32.85	31.90
Mar 11, 2025	32.41	0.13	0.40%	32.28	32.67	32.15
Mar 10, 2025	32.68	-0.07	-0.21%	32.75	33.13	32.47
Mar 7, 2025	32.92	-0.26	-0.78%	33.18	33.59	32.81
Mar 6, 2025	33.20	-0.33	-0.98%	33.53	33.65	33.04
Mar 5, 2025	33.70	0.75	2.28%	32.95	33.72	32.93
Mar 4, 2025	33.50	-0.21	-0.62%	33.71	33.98	33.35

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Royalty Pharma plc Company profile

About Royalty Pharma plc

Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Royalty Pharma plc revenues increased 8% to $2.29B. Net income applicable to common stockholders increased 25% to $619.7M. Revenues reflect Income from financial royalty assets increase of 5% to $2.07B, Other royalty income increase from $19M to $53.1M, Revenue from intangible royalty assets increase of 19% to $171.2M. Net income benefited from Other operating expenses decrease from $65.1M (expense) to $0K.

Industry:

Pharmaceuticals (NEC)

110 East 59th Street
NEW YORK
NEW YORK 10022
US